Suppr超能文献

肥胖重症患者拔管时去甲肾上腺素的使用:一项多中心验证的队列研究

Norepinephrine use at extubation in critically ill patients with obesity: a cohort study with multicenter validation.

作者信息

De Jong Audrey, Capdevila Mathieu, Aarab Yassir, Rabboni Francesca, Kozoriz Alina, Heupel Guillaume, Pensier Joris, Lakbar Ines, Monet Clément, Chanques Gérald, Jaber Samir

机构信息

Intensive Care Unit, Anesthesia and Critical Care Department, Saint Eloi Teaching Hospital, University Montpellier 1, Montpellier, France.

Phymed Exp INSERM U1046, CNRS UMR 9214, Montpellier, France.

出版信息

Intensive Care Med. 2025 Aug 6. doi: 10.1007/s00134-025-08066-x.

Abstract

PURPOSE

The aim of this study was to assess whether norepinephrine at the time of extubation increases reintubation rates in critically ill patients with obesity.

METHODS

The initial step was to analyze data that had been collected prospectively, using a retrospective approach-defined as the main cohort. Then, we validated our findings using data from a multicenter randomized-controlled trial (validation cohort). The primary objective was to compare reintubation within 7 days, between patients with norepinephrine and without norepinephrine at the time of extubation. The secondary objective was to assess norepinephrine doses at extubation, normalized to body weight.

RESULTS

Among the 3186 patients included in the main cohort, 837 had obesity. Among them, 213 (25%) were extubated with norepinephrine, with a median norepinephrine dose at extubation of 0.6 mg/h of absolute value which corresponds to 0.097 (0.04-0.17) µg/kg/min of real body weight. No significant difference in reintubation rates was observed between patients extubated with norepinephrine (16%) and those without (17%, p = 0.85). Among the 656 patients with obesity in the validation cohort, we observed similar results, with a reintubation rate of 18% in those extubated with norepinephrine and 15% in those without (p = 0.45). Similar results were observed in the 2349 patients without obesity.

INTERPRETATION

In critically ill patients with obesity, the use of norepinephrine at the time of extubation did not significantly increase the reintubation rates.

CLINICAL TRIAL REGISTRATION

NCT04014920 for the validation cohort.

摘要

目的

本研究旨在评估肥胖重症患者拔管时使用去甲肾上腺素是否会增加再插管率。

方法

第一步是采用回顾性方法分析前瞻性收集的数据,将其定义为主队列。然后,我们使用多中心随机对照试验的数据(验证队列)来验证我们的研究结果。主要目标是比较拔管时使用去甲肾上腺素的患者和未使用去甲肾上腺素的患者在7天内的再插管情况。次要目标是评估拔管时按体重标准化的去甲肾上腺素剂量。

结果

在主队列纳入的3186例患者中,837例患有肥胖症。其中,213例(25%)在拔管时使用了去甲肾上腺素,拔管时去甲肾上腺素的中位剂量绝对值为0.6 mg/h,相当于实际体重0.097(0.04 - 0.17)μg/kg/min。拔管时使用去甲肾上腺素的患者(16%)和未使用去甲肾上腺素的患者(17%,p = 0.85)之间,再插管率没有显著差异。在验证队列的656例肥胖患者中,我们观察到了类似的结果,拔管时使用去甲肾上腺素的患者再插管率为18%,未使用的患者为15%(p = 0.45)。在2349例非肥胖患者中也观察到了类似结果。

解读

在肥胖重症患者中,拔管时使用去甲肾上腺素并未显著增加再插管率。

临床试验注册

验证队列的注册号为NCT04014920。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验